Ken Griffin’s TScan Therapeutics TCRX Stock Holding History

Ken Griffin’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$322K	Buy	318,411 +155,534	+95%	+$166K	﹤0.01%	10317
2025 Q4	$163K	Sell	162,877 -227,870	-58%	-$330K	﹤0.01%	11220
2025 Q3	$711K	Buy	390,747 +171,760	+78%	+$304K	﹤0.01%	8300
2025 Q2	$318K	Buy	218,987 +164,595	+303%	+$238K	﹤0.01%	9684
2025 Q1	$75.1K	Sell	54,392 -88,225	-62%	-$191K	﹤0.01%	11830
2024 Q4	$434K	Buy	+142,617	New	+$646K	﹤0.01%	8877
2024 Q3	–	Sell	-157,963	Closed	-$924K	–	15235
2024 Q2	$924K	Buy	157,963 +146,531	+1,282%	+$1.15M	﹤0.01%	6746
2024 Q1	$90.8K	Buy	+11,432	New	+$71.9K	﹤0.01%	11487
2021 Q4	–	Sell	-11,922	Closed	-$99K	–	14743
2021 Q3	$99K	Buy	+11,922	New	+$111K	﹤0.01%	12887

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Ken Griffin's TCRX Position: Q1 2026 in Review

Ken Griffin increased its TScan Therapeutics (TCRX) stake by 95% in Q1 2026, buying an estimated $166K and bringing the position to 318,411 shares worth $322K. The position accounts for ﹤0.01% of the portfolio, ranked #10317.

Ken Griffin first reported a position in TCRX in Q3 2021 and has held it in 9 quarters since. The position peaked at $924K in Q2 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

Ken Griffin held 318,411 shares of TScan Therapeutics worth $322K as of Q1 2026.
Ken Griffin bought 155,534 TScan Therapeutics shares in Q1 2026, an estimated $166K.
TScan Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #10317 holding.
Ken Griffin first reported a position in TScan Therapeutics in Q3 2021 and has held it in 9 quarters since.
Ken Griffin's TScan Therapeutics position peaked at $924K in Q2 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.